Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9

Journal of Neuroimmunology

Volumn 80, Issue 1-2, 1997, Pages 38-46

  Stuve, Olaf ^a   Chabot, Sophie ^a,b   Jung, Sonia S ^a   Williams, Gary ^c   Yong, Voon Wee ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c BAYER AG   (Germany)

Author keywords

Cell trafficking; Extracellular matrix; Lymphocyte; Multiple sclerosis

Indexed keywords

CHEMOKINE; FIBRONECTIN; GELATINASE B; INTERFERON BETA SERINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ARTICLE; CELL MIGRATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN SECRETION;

CELL MIGRATION INHIBITION; CELL MOVEMENT; CELL SEPARATION; CHEMOKINE CCL2; CHEMOKINES; COLLAGENASES; HUMANS; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MACROPHAGE INFLAMMATORY PROTEIN-1; MATRIX METALLOPROTEINASE 9; RANTES; RNA, MESSENGER;

EID: 0031471371     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00134-3     Document Type: Article

References (65)

1. Abreu S.L. Suppression of experimental allergic encephalomyelitis by interferon. Immunol. Commun. 11:1982;1-17.
2. Albreu S.L. Interferon in experimental autoimmune encephalomyelitis (EAE): Effects of exogenous interferon on the antigen-enhanced transfer of EAE. Int. Arch. Allergy Appl. Immunol. 76:1985;302-307.
3. Albini A., Iwamoto Y., Kleinman K.K.et al. A rapid in vitro assay for quantifying the invasive potential of tumor cells. Cancer Res. 47:1987;3245-3329.
4. Arnason B.G.W., Dayal A., Qu Z.X., Jensen M.A., Genc K., Reder A.T. Mechanisms of action of interferon-β in multiple sclerosis. Springer Semin. Immunopathol. 18:1996;125-148.
5. Balasingam B., Yong V.W. Attenuation of astroglial reactivity by interleukin-10. J. Neurosci. 16:1996;2945-2955.
6. Berman J.W., Guida M.P., Warren J., Amat J., Brosnan C.F. Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J. Immunol. 156:1996;3017-3023.
7. Brod S.A., Marshall G.D. Jr., Henninger E.M.et al. Interferon-β1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis. Neurol. 46:1996;1633-1638.
8. Carr M.E., Alon R., Springer T.A. The C-C chemokine MCP-1 differentially modulates the avidity of beta-1 and beta-2 integrins on T lymphocytes. Immun. 4:1996;179-187.
9. Chabot, S., Williams, G., Yong, V.W., 1997. Microglial production of TNF-α is induced by activated T lymphocytes: Involvement of VLA-4 and inhibition by interferonβ-1b. 100, 604-612.
10. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparisons of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
11. DeClerck Y.A., Yean T.D., Ratzkin B.J.et al. Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells. J. Biol. Chem. 264:1989;17445-17453.
12. Dunon D., Piali L., Imhof B.A. To stick or not to stick: The new leukocyte homing paradigm. Curr. Opin. Cell Biol. 8:1996;714-723.
13. Fernandez O., Antiquedad A., Arbizu T., Capdevila A., de Castro P., Correa de Sa J.C., Garcia-Merino J.A., Izquierdo G., Magalhaes A., Montalban X., Zarranz J.J. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: A multicenter, randomized clinical trial. Multiple Sclerosis. 1:1995;67-69.
14. Friedland J.S. Chemokines and human infection. Clin. Sci. 88:1995;393-400.
15. Fuentes M.E., Durham S.K., Swerdel M.R., Lewin A.C., Barton D.S., Megill J.R., Bravo R., Lira S.A. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J. Immunol. 155:1995;5769-5776.
16. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41:1992;29-34.
17. Glabinski A.R., Tani M., Areas S., Stoler M.H., Tuohy V.K., Ransohoff R.M. Regulation and function of central nervous system chemokines. Int. J. Dev. Neurosci. 13:1995;153-165.
18. Godiska R., Chantry D., Dietsch G.N., Gray P.W. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 58:1995;167-176.
19. Grant G.M., Cobb J.K., Castillo B., Klebe R.J. Regulation of matrix metalloproteinases following cellular transformation. J. Cell Physiol. 167:1996;177-183.
20. Hall G.L., Compston A., Scolding N.J. Beta-interferon and multiple sclerosis. Trends Neurosci. 20:1997;63-67.
21. Hartung H.P., Achelos J.J., Zielasek J., Gold R., Koltzenburg M., Reiners K.H., Toyka V.T. Circulating adhesion molecules and inflammatory mediators in demyelination: A review. Neurology. 45:1995;22-32.
22. Hauzenberger D., Klominenk J., Sundquist K.G. Functional specialization of fibronectin-binding beta 1-integrins in T lymphocyte migration. J. Immunol. 153:1994;960-971.
23. Hohlfeld R., Meinl E., Weber F., Zipp F., Schmidt S., Sitgiu S., Goebels N., Voltz R., Spuler S., Iglesias A., Werkerle H. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology. 45:1995;33-38.
24. Jacobs L., Cookfair D., Rudick R.et al. Intramuscular interferon beta-1-alpha for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
25. Johnatty R.N., Taub D.D., Reeder S.P., Turcovski-Corrales S.M., Cottam D.W., Stephenson T.J., Rees R.C. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J. Immunol. 158:1997;2327-2333.
26. Kapila Y.L., Kapila S., Johnson P.W. Fibronectin and fibronectin fragments modulate the expression of proteinases and proteinase inhibitors in human periodontal ligament cells. Matrix Biol. 15:1996;251-261.
27. Karpus W.J., Lukacs N.W., McRae B.L., Strieter R.M., Kunkel S.L., Miller S.D. An important role for the chemokine macrophage inflammatory protein-1 pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155:1995;5003-5010.
28. Larsen C.G., Anderson A.O., Appella E., Oppenheim J.J., Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for lymphocytes. Science. 243:1989;1464-1466.
29. Laub D.T., Proost P., Murphy W.J., Anver M., Logo D.L., Van Damme J., Oppenheim J.J. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J. Clin. Invest. 95:1995;1370-1376.
30. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:1995;4379-4389.
31. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vivo migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-853.
32. Lira S.A., Zalamea P., Heinrich J.N., Fuentes M.E., Carrasco D., Lewin A.C., Barton D.S., Durham S., Bravo R. Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells. J. Exp. Med. 180:1994;2039-2048.
33. Lloyd A.R., Oppenheim J.J., Kelvin D.J., Taub B.B. Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. Immunol. 156:1996;932-938.
34. Lublin F.D., Whitaker J.N., Eidelman B.H., Miller A.E., Arnason B.G.W., Burks J.S. Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference. Neurol. 46:1996;12-18.
35. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.
36. Masure S., Proost P., Van Damme J., Opdenakker G. Purification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 198:1991;391-398.
37. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays. 14:1992;455-463.
38. Miyagishi R., Kikuchi S., Fukazawa T., Tashiro K. Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neurol. Sci. 129:1995;223-227.
39. Murphy W.J., Tian J.G., Asai O., Funakoshi S., Rotter P., Henry M., Strieter R.M., Lunkel S.L., Longo D.L., Taub D.D. Chemokines and T lymphocyte activation -2. Facilitation of human cell trafficking in severe combined immunodeficiency mice. J. Immunol. 156:1996;2104-2111.
40. Noronha A., Toscas A., Jensen M.A. Interferon beta augments suppressor cell function in multiple sclerosis. Ann. Neurol. 27:1990;207-210.
41. Noronha A., Toscas A., Jensen M.A. Interferon decreases T cell activation and interferon production in multiple sclerosis. J. Neuroimmunol. 46:1993;145-154.
42. Ostergaard H.L., Ma E.A. Fibronectin induces phosphorylation of a 120-kDa protein and synergizes with the T cell receptor to activate cytotoxic T cell clones. Eur. J. Immunol. 25:1995;252-256.
43. Paty, D.W., Li, D.K.B., The UBS MS/MRI Study Group, The IFNβ Multiple Sclerosis Study Group, 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurol. 43, 662-667.
44. Ransohoff R.M., Hamilton T.A., Tani M., Stoler M.H., Shicj H.E., Major J.A., Estes M.L., Thomas D.M., Tuohy V.K. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J. 7:1993;592-600.
45. Rosenberg G.A., Dencoff J.E., Correa N. Jr., Reiners M., Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurol. 46:1996;1626-1632.
46. Rudick R.A., Carpenter C.S., Cookfair D.L., Tuohy V.K., Ransohoff R.M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurol. 43:1993;2080-2087.
47. Rudick R.A., Ransohoff R.M., Peppler R., Mendendorp S.V., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann. Neurol. 40:1996;618-627.
48. Schall T., Bacon K., Toy K., Goeddel D. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 347:1990;669-671.
49. Schall T.J., Bacon K., Camp D.R.R., Kaspari J.W., Goeddel D.V. Human macrophage inflammatory protein α (MIP-1α) and MIP-1 chemokines attract distinct populations of lymphocytes. J. Exp. Med. 177:1993;1821-1825.
50. Stinissen P., Raus J., Zhang J. Autoimmune pathogenesis of multiple sclerosis: Role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol. 17:1997;33-75.
51. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Williams G., Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloprotease-9. Ann. Neurol. 40:1996;853-863.
52. Tanaka Y., Adams D.H., Hubacher S.et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β Nature. 361:1993;79-82.
53. Tani M., Ransohoff R.M. Do chemokines mediate inflammatory cell invasion of the central nervous system parenchyma? Brain Pathol. 4:1994;135-143.
54. Tani M., Fuentes M.E., Peterson J.W., Trapp B.D., Durham S.K., Loy J.K., Bravo R., Ransohoff R.M., Lira S.A. Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J. Clin. Invest. 98:1996;529-539.
55. Taub D.D., Key M.L., Clark D., Turcovski-Corrales S.M. Chemotaxis of T lymphocytes on extracellular matrix proteins. Analysis of the in vitro method to quantitate chemotaxis of human T cells. J. Immunol. Methods. 184:1995;187-198.
56. Taub D.D., Turcovski-Corrales S.M., Key M.L., Longo D.L., Murphy W. Chemokines and T lymphocyte activation - 1. chemokines costimulate human T lymphocyte activation in vitro. J. Immunol. 156:1996;2095-2103.
57. The IFNβ Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurol. 43:1993;655-661.
58. The IFN Multiple Sclerosis Study Group Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurol. 45:1995;1277-1285.
59. Uhm J.H., Dooley N.P., Villemure J.G., Yong V.W. Mechanisms of glioma invasion: Role of matrix-metalloproteinases. Can. J. Neurol. Sci. 24:1997;3-15.
60. Vaddi K., Newton R.C. Regulation of monocyte integrin expression by β-family chemokines. J. Immunol. 153:1994;4721-4732.
61. Werb Z., Tremble P., Damsky C.H. Regulation of extracellular matrix degradation by cell-extracellular matrix interactions. Cell Differentiation Dev. 32:1990;299-306.
62. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J. 5:1991;2145-2154.
63. Woessner J.F. Jr. The family of matrix metalloproteinases. Ann. N.Y. Acad. Sci. 32:1994;11-21.
64. Xia M., Leppert D., Hauser S.L., Sreedharan S.P., Nelson P.J., Krensky A.M., Goetzl E.J. Stimulus specificity of matrix metalloprotease dependence of human T cell migration through a model basement membrane. J. Immunol. 156:1996;160-167.
65. Yu M., Nishiyama A., Trapp B.D., Tuohy V.K. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64:1996;91-100.